Literature DB >> 32425698

Will the Colombian intensive care units collapse due to the COVID-19 pandemic?

Diego Andres Díaz-Guio1,2, Wilmer E Villamil-Gómez3,4,5,6, Luis Dajud7, Carlos E Pérez-Díaz8,9, D Katterine Bonilla-Aldana5,6,10,11, Alvaro Mondragon-Cardona6,12,13,14, Jaime A Cardona-Ospina5,6,11,15,16,17,18, José F Gómez19, Alfonso J Rodríguez-Morales5,6,11,15,16,17,18.   

Abstract

Entities:  

Keywords:  COVID-19; Colombia; Critical care; Intensive care units; SARS-CoV-2

Mesh:

Year:  2020        PMID: 32425698      PMCID: PMC7229742          DOI: 10.1016/j.tmaid.2020.101746

Source DB:  PubMed          Journal:  Travel Med Infect Dis        ISSN: 1477-8939            Impact factor:   6.211


× No keyword cloud information.
Dear Editor, The current Coronavirus Disease 2019 (COVID-19) pandemic, due to the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), further impacts already precarious healthcare infrastructures that are already stretched in Latin America [1]. One of the major concerns in this setting is the management of severe cases of COVID-19. Some estimates indicate that between 10 and 30% of patients with COVID-19 will require admittance to an intensive care unit (ICU) [2]. In countries with limited resources, a relative, but particularly absolute increase in the number of patients requiring ICU may overcome existing infrastructures [3,4]. This is the potential scenario of some countries in Latin America, such as Ecuador, that have apparently already saturated their capacities [5]. For others, such as Colombia, the question remains if ICU will collapse in terms of capacity. The COVID-19 arrived in Latin America in February 26, 2020, with the first case diagnosed in Brazil [4,6]. After that on March 6, 2020, the first case was diagnosed in Colombia. Some 60 days after the first case (May 4, 2020), a total of 7973 cases have been confirmed by RT-PCR, at the National Institute of Health (www.ins.gov.co) and the national collaborating laboratory network for SARS-CoV-2 diagnosis. The trend shows that a still increasing daily number of new cases (Fig. 1 ), but from the total, 1807 cases (22.7%) have recovered (negative follow-up RT-PCR) and 358 (4.5%) have died. Among those 5808 active cases, 90.4% of them have been managed at home (asymptomatic and mild cases), 7.5% have been hospitalized (moderate cases) and 2.1% (120) have been admitted to ICU (severe cases).
Fig. 1

A. Daily new cases reported of confirmed SARS-CoV-2 in Colombia, first 60 days. B. Relationship between severe COVID-19 cases requiring ICU and ICU beds capacities, by departments, cumulated during the first 60 days in Colombia.

A. Daily new cases reported of confirmed SARS-CoV-2 in Colombia, first 60 days. B. Relationship between severe COVID-19 cases requiring ICU and ICU beds capacities, by departments, cumulated during the first 60 days in Colombia. With 5845 beds of ICU in Colombia (https://bit.ly/2ytRapI), those figures are not currently concerning regarding the occupancy due to COVID-19. Fortunately, 32.5% (39) corresponded to Bogota (capital district) where there is a capacity of >1000 ICU beds (Fig. 1), followed by Valle del Cauca, 36 (30%), where the capacity is > 800 ICU beds (Fig. 1). The highest number of severe COVID-19 cases requiring ICU is observed in departments with higher ICU capacity (Fig. 1). Nevertheless, there are five departments of Colombia, out of 32 and the capital district, without ICU. One of them is Amazonas, that have reported 229 cases. The other four departments, Guaviare, Guania, Vaupes and Vichada, have not reported cases to date (May 4, 2020). Although there is too much to do, and this has been planned by the Ministry of Health of Colombia (MoH), such as the proposed hospital capacity expansion, the current balance is positive for Colombia, after the implemented measures. The MoH has proposed a four-phase plan including an amplification of the installed capacity (releasing 50% of the ICU beds, to make 2650 beds available) (phase 1), optimize the installed capacity (conversion of 2500 intermediate care units to ICU providing mechanical ventilation) (phase 2), extension of the installed capacity (creation of 2500 new ICU) (phase 3), and the critical extension (with 2,176 additional new ICU) (phase 4), to finally have 9826 ICU beds (an increase of 371%). What is unclear is the timing of this influx of patients and whether or not it will happen. With certainty, flattening the curve or decreasing the speed of spread of the epidemic will become a cumbersome task for public health professionals and clinicians all over the country. Up to May 17, 2020, Colombia has reported 14,939 confirmed COVID-19 cases (293.6 cases/1,000,000 inhabitants), 24.01% recovered and 3.76% died.

Declaration of competing interest

None.
  4 in total

Review 1.  COVID-19: Biosafety in the Intensive Care Unit.

Authors:  Diego Andrés Díaz-Guio; Yimmy Díaz-Guio; Valentina Pinzón-Rodas; Ana Sofía Díaz-Gomez; Jorge Andrés Guarín-Medina; Yesid Chaparro-Zúñiga; Alejandra Ricardo-Zapata; Alfonso J Rodriguez-Morales
Journal:  Curr Trop Med Rep       Date:  2020-08-27

2.  Clinical effectiveness of drugs in hospitalized patients with COVID-19: a systematic review and meta-analysis.

Authors:  Roberto Ariel Abeldaño Zuñiga; Silvia Mercedes Coca; Giuliana Florencia Abeldaño; Ruth Ana María González-Villoria
Journal:  Ther Adv Respir Dis       Date:  2021 Jan-Dec       Impact factor: 4.031

3.  Dengue and COVID-19, overlapping epidemics? An analysis from Colombia.

Authors:  Jaime A Cardona-Ospina; Kovy Arteaga-Livias; Wilmer E Villamil-Gómez; Carlos E Pérez-Díaz; D Katterine Bonilla-Aldana; Álvaro Mondragon-Cardona; Marco Solarte-Portilla; Ernesto Martinez; Jose Millan-Oñate; Eduardo López-Medina; Pio López; Juan-Carlos Navarro; Luis Perez-Garcia; Euler Mogollon-Rodriguez; Alfonso J Rodríguez-Morales; Alberto Paniz-Mondolfi
Journal:  J Med Virol       Date:  2020-07-11       Impact factor: 20.693

4.  Characteristics, management and outcomes of critically ill COVID-19 patients admitted to ICU in hospitals in Bangladesh: a retrospective study.

Authors:  Ayan Saha; Mohammed Moinul Ahsan; Tarek-Ul Quader; Mohammad Umer Sharif Shohan; Sabekun Naher; Preya Dutta; Al-Shahriar Akash; H M Hamidullah Mehedi; Asm Arman Ullah Chowdhury; Hasanul Karim; Tazrina Rahman; Ayesha Parvin
Journal:  J Prev Med Hyg       Date:  2021-04-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.